Phase 2 Completed N=52 Randomized Quadruple-blind Treatment

Treatment of Depression in Parkinson's Disease Trial

Parkinson's Disease · Depression

Source: ClinicalTrials.gov NCT00062738 ↗

Enrolled (actual)

Serious AEs

5.8%

Results posted

Mar 2013

Primary outcomePrimary: Hamilton Depression Scale — 10.84; 12.45; 15.81 units on a scale

Summary

The goal of this study is to evaluate the effectiveness and safety of two antidepressants--nortriptyline and paroxetine, compared to placebo in patients with Parkinson's disease and depression.

Outcome Measures

Outcome	Result	p-value
PRIMARY Hamilton Depression Scale	10.84; 12.45; 15.81	—
SECONDARY Percent Responders	53; 11; 24	<.05 sig

Eligibility Criteria

inclusion criteria

Parkinson's disease without dementia.
Depression.
Males or females.

exclusion criteria

Psychosis
Heart block

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00062738). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.